We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
- Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose...
The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX PR Newswire NEW YORK, April 9, 2024 NEW YORK, April 9, 2024 /PRNewswire/...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator...
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX PR Newswire NEW YORK, April 5, 2024 NEW YORK, April 5...
- Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations...
The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX PR Newswire NEW YORK, April 2, 2024...
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders PR Newswire NEW YORK, March 29, 2024 NEW YORK, March 29, 2024...
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX PR Newswire NEW YORK, March 26, 2024 NEW YORK, March 26, 2024...
INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINE PR Newswire SAN...
The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire NEW YORK, March 22, 2024 NEW YORK, March 22, 2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2 | -10.101010101 | 1.98 | 2.025 | 1.7 | 1925026 | 1.87979654 | CS |
4 | -1.06 | -37.323943662 | 2.84 | 2.89 | 1.7 | 2286865 | 2.27828811 | CS |
12 | -14.57 | -89.1131498471 | 16.35 | 19.9488 | 1.7 | 3449595 | 5.50134078 | CS |
26 | -14.37 | -88.9783281734 | 16.15 | 19.9488 | 1.7 | 2378771 | 8.43402626 | CS |
52 | -27.79 | -93.9803855259 | 29.57 | 30.49 | 1.7 | 1762316 | 12.78037946 | CS |
156 | -19.22 | -91.5238095238 | 21 | 41.9297 | 1.7 | 1310291 | 18.46071521 | CS |
260 | -19.22 | -91.5238095238 | 21 | 41.9297 | 1.7 | 1310291 | 18.46071521 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions